Open access
Open access
Powered by Google Translator Translator

Phase 2 RCT | Efficacy of preoperative mFOLFIRINOX vs. mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas.

15 Jul, 2022 | 12:29h | UTC

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the PancreasThe A021501 Phase 2 Randomized Clinical Trial – JAMA Oncology (free for a limited period)

Editorial: The Continued Struggle for Defining a Role for Radiotherapy in Pancreas Cancer – JAMA (free for a limited period)

News Release: Preoperative combination chemotherapy improved survival in patients with pancreatic cancer – The University of Texas MD Anderson Cancer Center

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.